Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Drug-induced liver injury

  • Suh, Jeong Ill (Department of Internal Medicine, College of Medicine, Dongguk University)
  • Received : 2019.07.30
  • Accepted : 2019.08.22
  • Published : 2020.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Drug-induced liver injury (DILI), including herbal and dietary supplement hepatotoxicity, is often passed lightly; however, it can lead to the requirement of a liver transplant or may even cause death because of liver failure. Recently, the American College of Gastroenterology, Chinese Society of Hepatology and European Association for the Study of the Liver guidelines for the diagnosis and treatment of DILI have been established, and they will be helpful for guiding clinical treatment decisions. Roussel Uclaf Causality Assessment Method scoring is the most commonly used method to diagnose DILI; however, it has some limitations, such as poor validity and reproducibility. Recently, studies on new biomarkers have been actively carried out, which will help diagnose DILI and predict the prognosis of DILI. It is expected that the development of new therapies such as autophagy inducers and various other technologies of the fourth industrial revolution will be applicable to DILI research.

Keywords

References

  1. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-34. https://doi.org/10.1053/j.gastro.2008.09.011
  2. Hayashi PH, Bjornsson ES. Long-term outcomes after drug-induced liver injury. Curr Hepatol Rep 2018;17:292-9. https://doi.org/10.1007/s11901-018-0411-0
  3. Zhu Y, Niu M, Chen J, Zou ZS, Ma ZJ, Liu SH, et al. Hepatobiliary and pancreatic: comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients. J Gastroenterol Hepatol 2016;31:1476-82. https://doi.org/10.1111/jgh.13323
  4. Lee WJ, Kim HW, Lee HY, Son CG. Systematic review on herb-induced liver injury in Korea. Food Chem Toxicol 2015;84:47-54. https://doi.org/10.1016/j.fct.2015.06.004
  5. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005;165:1363-9. https://doi.org/10.1001/archinte.165.12.1363
  6. Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J 2006;8:E48-54. https://doi.org/10.1208/aapsj080106
  7. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014;109:950-66. https://doi.org/10.1038/ajg.2014.131
  8. Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int 2017;11:221-41. https://doi.org/10.1007/s12072-017-9793-2
  9. European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol 2019; 70:1222-61. https://doi.org/10.1016/j.jhep.2019.02.014
  10. Fontana RJ, Seeff LB, Andrade RJ, Bjornsson E, Day CP, Serrano J, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010;52:730-42. https://doi.org/10.1002/hep.23696
  11. Devarbhavi H. An update on drug-induced liver injury. J Clin Exp Hepatol 2012;2:247-59. https://doi.org/10.1016/j.jceh.2012.05.002
  12. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-6. https://doi.org/10.1016/0168-8278(90)90124-A
  13. Visentin M, Lenggenhager D, Gai Z, Kullak-Ublick GA. Drug-induced bile duct injury. Biochim Biophys Acta Mol Basis Dis 2018;1864:1498-506. https://doi.org/10.1016/j.bbadis.2017.08.033
  14. Wang T, Zhao X, Shao C, Ye L, Guo J, Peng N, et al. A proposed pathologic sub-classification of drug-induced liver injury. Hepatol Int 2019;13:339-51. https://doi.org/10.1007/s12072-019-09940-9
  15. Ahmad J, Odin JA. Epidemiology and genetic risk factors of drug hepatotoxicity. Clin Liver Dis 2017;21:55-72. https://doi.org/10.1016/j.cld.2016.08.004
  16. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009;29:337-47. https://doi.org/10.1055/s-0029-1240002
  17. Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol 2012;107:1380-7. https://doi.org/10.1038/ajg.2012.138
  18. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30. https://doi.org/10.1016/0895-4356(93)90101-6
  19. Hayashi PH. Overview of causality assessment in drug-induced liver injury. Clin Liver Dis (Hoboken) 2017;9:29-33. https://doi.org/10.1002/cld.615
  20. Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology 2004;40:773. https://doi.org/10.1002/hep.20445
  21. Hayashi PH. Drug-induced liver injury network causality assessment: criteria and experience in the United States. Int J Mol Sci 2016;17:201. https://doi.org/10.3390/ijms17020201
  22. Antoine DJ, Williams DP, Kipar A, Jenkins RE, Regan SL, Sathish JG, et al. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci 2009;112:521-31. https://doi.org/10.1093/toxsci/kfp235
  23. McGill MR, Jaeschke H. Biomarkers of drug-induced liver injury. Adv Pharmacol 2019;85:221-39. https://doi.org/10.1016/bs.apha.2019.02.001
  24. Neuman MG. Biomarkers of drug-induced liver toxicity. Ther Drug Monit 2019;41:227-34. https://doi.org/10.1097/FTD.0000000000000610
  25. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008;47:2003-9. https://doi.org/10.1002/hep.22272
  26. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009;16:3041-53. https://doi.org/10.2174/092986709788803097
  27. Gijbels E, Vinken M. Mechanisms of drug-induced cholestasis. Methods Mol Biol 2019;1981:1-14. https://doi.org/10.1007/978-1-4939-9420-5_1
  28. Patel SJ, Milwid JM, King KR, Bohr S, Iracheta-Vellve A, Li M, et al. Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol 2012;30:179-83. https://doi.org/10.1038/nbt.2089
  29. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246-59. https://doi.org/10.1053/j.gastro.2010.04.001
  30. Bjornsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis 2014;34:115-22. https://doi.org/10.1055/s-0034-1375953
  31. Li H, He J, Jia W. The influence of gut microbiota on drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 2016; 12:31-40. https://doi.org/10.1517/17425255.2016.1121234
  32. Teschke R, Danan G. Diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease. Drug Saf 2016;39:729-44. https://doi.org/10.1007/s40264-016-0423-z
  33. Chalasani N, Regev A. Drug-induced liver injury in patients with preexisting chronic liver disease in drug development: how to identify and manage? Gastroenterology 2016;151:1046-51. https://doi.org/10.1053/j.gastro.2016.10.010
  34. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999.
  35. Reuben A. Hy's law. Hepatology 2004;39:574-8. https://doi.org/10.1002/hep.20081
  36. Lo Re V 3rd, Haynes K, Forde KA, Goldberg DS, Lewis JD, Carbonari DM, et al. Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy's law and a new prognostic model. Clin Gastroenterol Hepatol 2015;13:2360-8. https://doi.org/10.1016/j.cgh.2015.06.020
  37. Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Caliz I, Gonzalez-Jimenez A, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014;147:109-18. https://doi.org/10.1053/j.gastro.2014.03.050
  38. de Boer YS, Sherker AH. Herbal and dietary supplement-induced liver injury. Clin Liver Dis 2017;21:135-49. https://doi.org/10.1016/j.cld.2016.08.010
  39. Garcia-Cortes M, Stephens C, Lucena MI, Fernandez-Castaner A, Andrade RJ. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011;55:683-91. https://doi.org/10.1016/j.jhep.2011.02.007
  40. Teschke R, Wolff A, Frenzel C, Schwarzenboeck A, Schulze J, Eickhoff A. Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. World J Hepatol 2014;6:17-32. https://doi.org/10.4254/wjh.v6.i1.17
  41. Suh JI, Sakong JK, Lee K, Lee YK, Park JB, Kim DJ, et al. Anxiety and depression propensities in patients with acute toxic liver injury. World J Gastroenterol 2013;19:9069-76. https://doi.org/10.3748/wjg.v19.i47.9069
  42. Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, et al. Lessons learned from independent central review. Eur J Cancer 2009;45:268-74. https://doi.org/10.1016/j.ejca.2008.10.031
  43. Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009;137:856-64. https://doi.org/10.1053/j.gastro.2009.06.006
  44. Bateman DN, Dear JW, Thanacoody HK, Thomas SH, Eddleston M, Sandilands EA, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet 2014;383:697-704. https://doi.org/10.1016/S0140-6736(13)62062-0
  45. Singh S, Hynan LS, Lee WM; Acute Liver Failure Study Group. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci 2013; 58:1397-402. https://doi.org/10.1007/s10620-012-2512-x
  46. Hu PF, Xie WF. Corticosteroid therapy in drug-induced liver injury: pros and cons. J Dig Dis 2019;20:122-6. https://doi.org/10.1111/1751-2980.12697
  47. Hu PF, Wang PQ, Chen H, Hu XF, Xie QP, Shi J, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis 2016;17:618-27. https://doi.org/10.1111/1751-2980.12383
  48. Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-76. https://doi.org/10.1002/hep.23937
  49. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009;15:719-29. https://doi.org/10.1002/lt.21692
  50. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45. https://doi.org/10.1016/0016-5085(89)90081-4
  51. Rudraiah S, Zhang X, Wang L. Nuclear receptors as therapeutic targets in liver disease: are we there yet? Annu Rev Pharmacol Toxicol 2016;56:605-26. https://doi.org/10.1146/annurev-pharmtox-010715-103209
  52. Suh JI. Role of PXR and CAR in cholestasis. Korean J Hepatol 2006;12:5-15.
  53. Zhang J, Huang W, Chua SS, Wei P, Moore DD. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 2002;298:422-4. https://doi.org/10.1126/science.1073502
  54. Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos 2009;37:1611-21. https://doi.org/10.1124/dmd.109.027565
  55. Ni HM, Jaeschke H, Ding WX. Targeting autophagy for drug-induced hepatotoxicity. Autophagy 2012;8:709-10. https://doi.org/10.4161/auto.19659
  56. Huh D, Torisawa YS, Hamilton GA, Kim HJ, Ingber DE. Microengineered physiological biomimicry: organs-on-chips. Lab Chip 2012;12:2156-64. https://doi.org/10.1039/c2lc40089h
  57. Kimura H, Sakai Y, Fujii T. Organ/body-on-a-chip based on microfluidic technology for drug discovery. Drug Metab Pharmacokinet 2018;33:43-8. https://doi.org/10.1016/j.dmpk.2017.11.003
  58. Beckwitt CH, Clark AM, Wheeler S, Taylor DL, Stolz DB, Griffith L, et al. Liver 'organ on a chip'. Exp Cell Res 2018;363:15-25. https://doi.org/10.1016/j.yexcr.2017.12.023
  59. Xu Y, Dai Z, Chen F, Gao S, Pei J, Lai L. Deep learning for drug-induced liver injury. J Chem Inf Model 2015;55:2085-93. https://doi.org/10.1021/acs.jcim.5b00238
  60. Fraser K, Bruckner DM, Dordick JS. Advancing predictive hepatotoxicity at the intersection of experimental, in silico, and artificial intelligence technologies. Chem Res Toxicol 2018;31: 412-30. https://doi.org/10.1021/acs.chemrestox.8b00054
  61. Suh JI. Establishment of tertiary hospital including southeast clinical research center in the era of the 4th industrial revolution. In: Choi YJ, editor. The 58th annual meeting and international symposium of Korean Society of Life Science; 2017 Aug 3-4; Gyeongju, Korea. Busan: Korean Society of Life Science; 2017. p. 71.

Cited by

  1. Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases vol.8, pp.2, 2020, https://doi.org/10.14218/jcth.2020.00009
  2. Five Constituents Contributed to the Psoraleae Fructus-Induced Hepatotoxicity via Mitochondrial Dysfunction and Apoptosis vol.12, 2020, https://doi.org/10.3389/fphar.2021.682823
  3. Prediction of Drug-Induced Liver Toxicity Using SVM and Optimal Descriptor Sets vol.22, pp.15, 2020, https://doi.org/10.3390/ijms22158073
  4. Changes in Liver Function Test Results after Korean Medicine Treatment in Patients of a Korean Medicine Hospital: A Retrospective Chart Review vol.38, pp.4, 2020, https://doi.org/10.14406/acu.2021.028